Through predictive modelling, AI supports target identification, prediction of physicochemical properties and formulation strategy selection.

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize ...

The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

Xaira is an integrated biotechnology company built to deliver on the promise of AI to help transform the drug discovery and development process Dr. Ian McCaffery joins from AbbVie, where he served as ...

AI-driven small molecule discovery, which underlies most drugs on the market, is a challenge being tackled through science and technology ...

A coalition of health experts has asked the Union government to urgently revise the NLEM. They say the delay is restricting affordable access to newer essential cancer and biological therapies.

Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical ...

Anthropic also went a step further, saying it would develop drugs of its own. Head of life sciences Eric Kauderer-Abrams said ...

Process analytical technology enables data-driven scale-up by embedding real-time analytics from development through ...

Scientists have discovered that a topical anti-aging drug called ABT-263 can dramatically improve wound healing in older skin. The treatment works by removing damaged “senescent” cells that accumulate ...

Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced successful results ...